Study: Vaccine Suppresses Peanut Allergies in Mice

U-M researchers aim to develop a new immunotherapy that could alter the immune reactions to food. The result: extended relief from peanut allergies.

4:00 AM

Author | Beata Mostafavi

A vaccine may successfully turn off peanut allergy in mice, a new study shows.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Just three monthly doses of a nasal vaccine protected the mice from allergic reactions upon exposure to peanut, according to research from the Mary H. Weiser Food Allergy Center at the University of Michigan.

U-M researchers have spent nearly two decades developing a vaccine agent and have recently translated this work to the development of a vaccine to treat food allergies. In the new study, immunizing peanut allergic mice can redirect how immune cells responded to peanuts in allergic mice.

The new approach activates a different type of immune response that prevents allergic symptoms.

"We're changing the way the immune cells respond upon exposure to allergens," says lead author Jessica O'Konek, Ph.D., a research investigator at the food allergy center. "Importantly, we can do this after allergy is established, which provides for potential therapy of allergies in humans."

"By redirecting the immune responses, our vaccine not only suppresses the response but prevents the activation of cells that would initiate allergic reactions."

The study, funded by grants from Food Allergy Research & Education (FARE) and the Department of Defense, was published in the Journal of Allergy and Clinical Immunology. It was also funded by a gift from the Shaevsky Family Foundation. 

New approach to suppressing allergies

The mouse models studied responded to peanut allergies similarly as affected humans, with symptoms that included itchy skin and trouble breathing. The study assessed protection from allergic reactions two weeks after the final dose of vaccine was administered.

SEE ALSO: Successful Clinical Trial for Peanut Allergy Treatment Spreads Hope

Studies to determine duration of protection are ongoing, but researchers are encouraged that this approach will lead to long-lasting suppression of allergies.  

The findings are another step toward a potential clinical trial down the road to test the method in humans.

"Right now, the only FDA-approved way to address food allergy is to avoid the food or suppress allergic reactions after they have already started," O'Konek says. "Our goal is to use immunotherapy to change the immune system's response by developing a therapeutic vaccine for food allergies."

Fuel for future research

Next steps include further studies in mice to better understand the mechanisms responsible for the suppression of food allergies and to learn whether protection from peanut allergies can be extended for an even longer period of time. 

"Food allergy has exploded in prevalence and incidence, but we still know so little about it because there hasn't been that much research in the field," says senior author James Baker Jr., M.D., director of U-M's food allergy center. He is also the CEO of FARE.

"This research is also teaching us more about how food allergies develop and the science behind what needs to change in the immune system to treat them," Baker says.

This study was specifically funded by the DOD's Modulation of Food Allergy Responses with a Nanoemulsion-based Allergy Vaccine grant and FARE's New Investigators Award.


More Articles About: Lab Report Food Allergy Immunizations Allergy and Immunology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Health care provider loads syringe with measles vaccine
Health Lab
Measles: 10 things to know about immunization and prevention
Measles: 10 things to know about immunization and prevention
covid cell blue yellow sketched graphic
Health Lab
Sickle cell raises COVID risk, but vaccination lags
Vaccination against the coronavirus was much lower in adults and children with sickle cell disease despite a higher risk of severe COVID-19.
white bowls with allergens in each one
Health Lab
Measuring skin water loss predicts anaphylaxis during food allergy tests
Measuring skin water loss during food allergy tests may help predict anaphylaxis and keep patients safe. The method aims to detect the life threatening reaction before epinephrine injections are necessary
Syringes in a row on yellow backfround
Health Lab
New COVID-19 vaccine a good value for U.S., U-M team finds
A cost effectiveness analysis of the updated COVID-19 vaccine shows that it will save money in older adults and give good value for other adults.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
The Long-Term Care Data Cooperative: Your One Stop Shop for Nursing Home Data
In this episode, Donovan & Matt talk with health services researcher Betsy White from Brown University about a unique new resource for researchers called the Long-Term Data Cooperative, a provider-led data sharing collaboratory that puts together nursing home EHR data from EHR vendors that can be linked to Medicare claims. This powerful tool is made available to researchers through an online application process.
older gentleman getting vaccine arm rolled up
Health Lab
Many older adults want RSV vaccine, poll shows
RSV vaccines are now available to older adults for the first time; a poll gauges awareness and interest among those over 60.